Advanced Cancer Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2021-2026

Report Code: HCR 41756 Report Format: PDF + Excel

Advanced Cancer Diagnostics Market Overview

Advanced Cancer Diagnostics Market size was estimated at $6.8 billion in 2020, projected to grow at a CAGR of 12.3% during the forecast period 2021-2026. Advanced Cancer Diagnostics industry has witnessed huge demand owing to the rising prevalence of cancer cases globally. Cancer, also known as malignant neoplasm, is a group of disease characterized by irregular cell formation. Uncontrollable cell growth results in formation of malignant tumours that invade to adjacent body parts. Some biomarkers are used to assess an individual whether or not that person develops cancer. 

Recently, next generation sequencing (NGS) is adopted by clinical oncology to advance the personalized treatment of cancer. NGS is used to detect carriers of familiar cancer mutation, novel and rare cancer mutations, and provide appropriate target therapy. Immunohistochemistry is used to help find the difference between various types of cancer. It is extensively used in diagnosis of various cancers as specific tumor antigens are up-regulated in certain types of cancer. Biomarker testing or molecular testing or genetic testing is a group of tests that look for the molecular signs of health so that the doctor plans the best care. It is used to diagnose advanced-stage lung cancer patients to identify the presence of particular mutations. 

Breast, colorectal cancer, prostate, skin, stomach and lung cancer are some of the most common cancers according to World Health Organization (WHO). The rising number of cancer cases along with increasing patient awareness on cancer are the major factors driving the market growth. According to the WHO, Cancer is the leading cause of death globally, in 2020 it is reported that nearly 10 million deaths were caused by cancer.

Advanced Cancer Diagnostics Market Report Coverage

The report: “Advanced Cancer Diagnostics Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Advanced Cancer Diagnostics Market.
By Type: Next generation sequencing, Lab-on-a-chip, Cellular analysis, Real time PCR (RT_PCR), Multiplexed arrays, and High density microarrays
By Application: Breast, Cervical, Colorectal, Prostate, Lung, Skin, Blood, Liver, Kidney, Ovarian, Pancreatic cancer, and Others
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America), and Rest of the World (Middle East and Africa)

Key Takeaways 

  • Geographically, North America Advanced Cancer Diagnostics Market held the largest revenue share of 45% in 2020 owing to the rising number of cancer cases in this region.
  • According to WHO, 2.26 million new cases of breast cancer was reported in the year 2020, thus generating significant growth opportunity for service demand.
  • Increase in prevalence of breast cancer, increasing aging population, growing medical tourism in various developing countries are the other factors boosting the market growth and provide lucrative growth opportunities for the global market expansion.

Advanced Cancer Diagnostics Market: Market Share (%) by Region, 2020

Advanced Cancer Diagnostics Market

For more details on this report - Request for Sample

Advanced Cancer Diagnostics Market Segment Analysis – By Type:

Based on Type, Advanced Cancer Diagnostics Market is segmented into Next generation sequencing, Lab-on-a-chip, Cellular analysis, Real time PCR (RT_PCR), Multiplexed arrays, and High-density microarrays. The next-generation sequencing segment is accounted for the largest revenue market share in 2020. This is attributed to the advanced technology of NGS as it has progressed to the point that several laboratories are considering it for routine diagnostic use. When compared to other sequencing modalities, its speed, sensitivity and reduced cost per sample make it very appealing platform. Furthermore, as more genetic determinants of cancer are discovered, there is a greater need for multi-gene assays that sequence complete gene from patient's samples rapidly and accurately.  

Real time PCR is anticipated to grow with the fastest CAGR of 12.7% in the forecast period 2021-2026. RT-PCR is currently the most effective method to determine the amount of specific DNA in a complex biologic sample. RT-PCR has become most favorable option for the analysis of cancer markers these days owing to its capability to identify small mutations, down to single base changes. Such techniques are becoming easier and fast and are multiplexed.

Advanced Cancer Diagnostics Market Segment Analysis – By Application:

Based on Application, Advanced Cancer Diagnostics Market is segmented into Breast, Cervical, Colorectal, Prostate, Lung, Skin, Blood, Liver, Kidney, Ovarian, Pancreatic cancer, and Others. Breast Cancer segment is accounted for the largest revenue market share in 2020 owing to increase in prevalence of breast cancer cases globally. According to WHO, 2.26 million new breast cancer cases were reported globally in the year 2020. 

Application of next generation sequencing to breast cancer is associated with numerous advances and increases the understanding of the disease. Women aged between 50 to 75 years are said to have higher risk of developing breast cancer according to the United States Preventive Services Task Force (UPSPSTF). Kidney Cancer is poised to grow with the fastest CAGR of 13.00% in the forecast period 2021-2026. This is attributed to the increase in alcohol consumption and smoking habits that induce tumours in the liver and kidney.

Advanced Cancer Diagnostics Market Segment Analysis – By Geography:

Based on Geography, North America Advanced Cancer Diagnostics Market accounted for the 45% revenue share in 2020. This is majorly attributed to the rising number of accidents and presence of local key market players in this region. According to American Cancer Society, in the United States new cancer cases are 1,762,450 and deaths are 606,880 in 2019. Presence of various biotechnology and medical device manufacturing companies in this region is the major factor driving the market. Asia-Pacific is projected to grow with the fastest CAGR in the forecast period 2021-2026 owing to its growing medical tourism, presence of skilled biotechnologists, increase in geriatric population, rising health care expenditure coupled with government initiatives.

Advanced Cancer Diagnostics Market Drivers

Rising Government Initiatives:

Enormous efforts by the government and the global health organizations like WHO and Center of Disease Control to create awareness among the people regarding cancer, and reduce the disease burden is predicted to favour the advanced cancer diagnostics market expansion. For example, WHO collaborated with the International Agency for Research on Cancer (IARC) and some other UN organizations in order to control the prevalence of non-communicable diseases.

Advanced Cancer Diagnostics Market Challenges

Lack of Awareness in Emerging Economies:

Lack of awareness on cancer among people in emerging countries is poised to hinder the growth of the advanced cancer diagnostics market. In developing countries especially larger population countries like China, India, Brazil, South Africa, it has become very difficult to reach the rural people to provide healthcare facilities, as there is a lack of proper healthcare infrastructure, skilled technicians and medical professionals.

Advanced Cancer Diagnostics Market Segment Landscape:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Advanced Cancer Diagnostics Market. Advanced Cancer Diagnostics Market top 10 companies are Biocept, Roche, Beckman Coulter Inc., Abbott Laboratories, Becton Dickinson & Co., GE Healthcare, Affymetrix Inc., Gen Probe Inc. and Biotheranostics.

Acquisitions/Product Launches:

  • In March 2020, Siemens Healthineers has received CE mark for its AI-Pathway Companion Prostate Cancer. This approval enabled the company to market their product in Europe as a medical device.

Related Reports:

Report Code: HCR 0195

Report Code: HCR 0068

For more Lifesciences and Healthcare Market reports, please click here
1. Advanced Cancer Diagnostics Market - Overview
    1.1 Definitions and Scope
2. Advanced Cancer Diagnostics Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Type
    2.3 Key trends by Application
    2.4 Key trends by End User
    2.5 Key trends by Geography
3. Advanced Cancer Diagnostics Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split - Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis – Average Selling Price
4. Advanced Cancer Diagnostics Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Advanced Cancer Diagnostics Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Advanced Cancer Diagnostics Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Advanced Cancer Diagnostics Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Advanced Cancer Diagnostics Market – By Type (Market Size –$Million/$Billion)
    8.1 Next Generation Sequencing
    8.2 Lab-On-A-Chip
    8.3 Cellular Analysis
    8.4 Real Time PCR
    8.5 Multiplexed Arrays
    8.6 High Density Micro Arrays
9. Advanced Cancer Diagnostics Market – By Application (Market Size –$Million/$Billion)
    9.1 Breast Cancer
    9.2 Cervical Cancer
    9.3 Prostate Cancer
    9.4 Lung Cancer
    9.5 Skin Cancer
    9.6 Blood Cancer
    9.7 Kidney Cancer
    9.8 Ovarian Cancer
    9.9 Pancreatic Cancer
    9.10 Others
10. Advanced Cancer Diagnostics Market – By End User(Market Size –$Million/$Billion)
    10.1 Hospitals
    10.2 Clinics
    10.3 Research Institutes
11. Advanced Cancer Diagnostics Market - By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5  Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Advanced Cancer Diagnostics Market - Entropy
13. Advanced Cancer Diagnostics Market – Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Advanced Cancer Diagnostics Market – Key Company List by Country Premium Premium
15. Advanced Cancer Diagnostics Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10  Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Advanced Cancer Diagnostics Product Outlook Market 2019-2024 ($M)
1.1 Genomics Based Diagnostics Market 2019-2024 ($M) - Global Industry Research
1.2 Epigenomics Based Diagnostics Market 2019-2024 ($M) - Global Industry Research
1.3 Cellular Analysis Based Diagnostics Market 2019-2024 ($M) - Global Industry Research
1.4 Proteomics Based Diagnostics Market 2019-2024 ($M) - Global Industry Research
2.Global Advanced Cancer Diagnostics Product Outlook Market 2019-2024 (Volume/Units)
2.1 Genomics Based Diagnostics Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Epigenomics Based Diagnostics Market 2019-2024 (Volume/Units) - Global Industry Research
2.3 Cellular Analysis Based Diagnostics Market 2019-2024 (Volume/Units) - Global Industry Research
2.4 Proteomics Based Diagnostics Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Advanced Cancer Diagnostics Product Outlook Market 2019-2024 ($M)
3.1 Genomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
3.2 Epigenomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
3.3 Cellular Analysis Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
3.4 Proteomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
4.South America Advanced Cancer Diagnostics Product Outlook Market 2019-2024 ($M)
4.1 Genomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
4.2 Epigenomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
4.3 Cellular Analysis Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
4.4 Proteomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
5.Europe Advanced Cancer Diagnostics Product Outlook Market 2019-2024 ($M)
5.1 Genomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
5.2 Epigenomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
5.3 Cellular Analysis Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
5.4 Proteomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
6.APAC Advanced Cancer Diagnostics Product Outlook Market 2019-2024 ($M)
6.1 Genomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
6.2 Epigenomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
6.3 Cellular Analysis Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
6.4 Proteomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
7.MENA Advanced Cancer Diagnostics Product Outlook Market 2019-2024 ($M)
7.1 Genomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
7.2 Epigenomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
7.3 Cellular Analysis Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research
7.4 Proteomics Based Diagnostics Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
2.Canada Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
3.Mexico Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
4.Brazil Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
5.Argentina Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
6.Peru Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
7.Colombia Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
8.Chile Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
9.Rest of South America Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
10.UK Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
11.Germany Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
12.France Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
13.Italy Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
14.Spain Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
15.Rest of Europe Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
16.China Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
17.India Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
18.Japan Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
19.South Korea Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
20.South Africa Advanced Cancer Diagnostics Market Revenue, 2019-2024 ($M)
21.North America Advanced Cancer Diagnostics By Application
22.South America Advanced Cancer Diagnostics By Application
23.Europe Advanced Cancer Diagnostics By Application
24.APAC Advanced Cancer Diagnostics By Application
25.MENA Advanced Cancer Diagnostics By Application